Author

Eita Uchida

Children's of AlabamaORCID 0000-0002-3056-5446Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Rintaro HashizumeiD· 3 shared Jun WatanabeiD· 2 shared Kentaro Mineji· 2 shared Samantha GaddiD· 2 shared Adam L. GreeniD· 1 shared Ali ShilatifardiD· 1 shared Claudia Bigas· 1 shared Daichi Hagita· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Rintaro HashizumeORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

YAP-TEAD-driven CPA4 promotes NF2-deficient meningioma growth

Kentaro Mineji, Katerina Petrosky, Ryosuke Otsuji, Yasuhide Makino, Yuji Kibe, Eita Uchida, Daichi Hagita, Neha Singaravelan, Yukitomo Ishi, Shigeru Yamaguchi, Long‐Sheng Chang, Samantha Gadd, Rintaro Hashizume

This study identifies CPA4 as a YAP-TEAD-driven effector in NF2-deficient meningioma, showing its role in tumor growth and sensitivity to TEAD inhibitors.

bioRxiv · Aug 7, 2026 · PreprintCancer Biology

FCD-11: A First-in-Class COMPASS Inhibitor in Cancer Therapeutics

Zibo Zhao, Meenal Karunanidhi, Sarah R. Gold, Luke St John, Rukkia Liaqat, Marta Iwanaszko, Claudia Bigas, Eita Uchida, Kentaro Mineji, Jun Watanabe, Salvador Aznar-Benitah, Rintaro Hashizume, Rama K. Mishra, Ali Shilatifard

The paper identifies and characterizes FCD-11, a first-in-class COMPASS inhibitor that reduces tumor size and extends survival in breast cancer models.

bioRxiv · Jul 31, 2026 · PreprintBiochemistry

Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical Models

Yusuke Tomita, Gabrielle Link, Yi Ge, Emma R.H. Gold, Herminio Joey Cardona, Megan M. Romero, Samantha Gadd, Jun Watanabe, Eita Uchida, Rintaro Hashizume, Yoshihiro Tanaka, Nozomu Takata, Gonzalo Piñero, Dolores Hambardzumyan, Ivan Spasojević, , Oren Josh Becher

This study evaluates combination therapy of CDK4/6 and MEK inhibitors in DMG models, finding survival benefits in GEM but not PDX models.

PLoS ONE · Dec 22, 2025Peer-reviewedCancer Biology